Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Targeting RAS in pediatric cancer: is it becoming a reality?

Vaseva AV, Yohe ME.

Curr Opin Pediatr. 2020 Feb;32(1):48-56. doi: 10.1097/MOP.0000000000000856.

PMID:
31815779
2.

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.

Blake DR, Vaseva AV, Hodge RG, Kline MP, Gilbert TSK, Tyagi V, Huang D, Whiten GC, Larson JE, Wang X, Pearce KH, Herring LE, Graves LM, Frye SV, Emanuele MJ, Cox AD, Der CJ.

Sci Signal. 2019 Jul 16;12(590). pii: eaav7259. doi: 10.1126/scisignal.aav7259.

3.

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.

Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, Pecot CV, Rashid N, Houghton PJ, Wennerberg K, Cox AD, Der CJ.

Cancer Cell. 2018 Nov 12;34(5):807-822.e7. doi: 10.1016/j.ccell.2018.10.001.

4.

Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies.

Waters AM, Ozkan-Dagliyan I, Vaseva AV, Fer N, Strathern LA, Hobbs GA, Tessier-Cloutier B, Gillette WK, Bagni R, Whiteley GR, Hartley JL, McCormick F, Cox AD, Houghton PJ, Huntsman DG, Philips MR, Der CJ.

Sci Signal. 2017 Sep 26;10(498). pii: eaao3332. doi: 10.1126/scisignal.aao3332.

5.

Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.

Klingler S, Guo B, Yao J, Yan H, Zhang L, Vaseva AV, Chen S, Canoll P, Horner JW, Wang YA, Paik JH, Ying H, Zheng H.

Cancer Res. 2015 May 15;75(10):2109-19. doi: 10.1158/0008-5472.CAN-14-3122. Epub 2015 Mar 25.

6.

Identification of p53 in mitochondria.

Vaseva AV, Moll UM.

Methods Mol Biol. 2013;962:75-84. doi: 10.1007/978-1-62703-236-0_6.

PMID:
23150438
7.

p53 opens the mitochondrial permeability transition pore to trigger necrosis.

Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM.

Cell. 2012 Jun 22;149(7):1536-48. doi: 10.1016/j.cell.2012.05.014.

8.

An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.

Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellmann C, Taylor MJ, Weissenboeck M, Graeber TG, Kogan SC, Vakoc CR, Lowe SW.

Genes Dev. 2011 Aug 1;25(15):1628-40. doi: 10.1101/gad.17269211. Erratum in: Genes Dev. 2011 Sep 15;25(18):1997. Fellman, Christof [corrected to Fellmann, Christof].

9.

Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.

Vaseva AV, Yallowitz AR, Marchenko ND, Xu S, Moll UM.

Cell Death Dis. 2011 May 12;2:e156. doi: 10.1038/cddis.2011.39.

10.

p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis.

Talos F, Abraham A, Vaseva AV, Holembowski L, Tsirka SE, Scheel A, Bode D, Dobbelstein M, Brück W, Moll UM.

Cell Death Differ. 2010 Dec;17(12):1816-29. doi: 10.1038/cdd.2010.131.

11.

Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.

Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, Shields JM, Sartor CI.

Clin Cancer Res. 2010 Feb 1;16(3):912-23. doi: 10.1158/1078-0432.CCR-09-1324. Epub 2010 Jan 26.

12.

Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.

Zimmer Y, Vaseva AV, Medová M, Streit B, Blank-Liss W, Greiner RH, Schiering N, Aebersold DM.

Cancer Lett. 2010 Mar 28;289(2):228-36. doi: 10.1016/j.canlet.2009.08.017. Epub 2009 Sep 23.

PMID:
19783361
13.

The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells.

Vaseva AV, Marchenko ND, Moll UM.

Cell Cycle. 2009 Jun 1;8(11):1711-9. Epub 2009 Jun 30.

14.

The mitochondrial p53 pathway.

Vaseva AV, Moll UM.

Biochim Biophys Acta. 2009 May;1787(5):414-20. doi: 10.1016/j.bbabio.2008.10.005. Epub 2008 Oct 25. Review.

15.

Repression of cyclin D1 as a target for germ cell tumors.

Freemantle SJ, Vaseva AV, Ewings KE, Bee T, Krizan KA, Kelley MR, Hattab EM, Memoli VA, Black CC, Spinella MJ, Dmitrovsky E.

Int J Oncol. 2007 Feb;30(2):333-40.

PMID:
17203214
16.

Negative feedback at the level of nuclear receptor coregulation. Self-limitation of retinoid signaling by RIP140.

White KA, Yore MM, Warburton SL, Vaseva AV, Rieder E, Freemantle SJ, Spinella MJ.

J Biol Chem. 2003 Nov 7;278(45):43889-92. Epub 2003 Sep 22.

Supplemental Content

Loading ...
Support Center